Data Supports Temelimab's Potential to Treat Disease Progression in MS
Long-term neuroprotective effects confirmed in patients treated up to two years
Sustained benebits on cortical and thalamic atrophy and my ...
Top line results expected in spring 2019
GKT 831 exhibited a favorable safety profile throughout the study
No drop outs or treatment interruptions due to pruritus
2 SAEs recorded in the study, both unrelat ...
10-for-1 reverse stock split: 10 existing shares with par value of €0.10 for 1 new share with par value of €1.00
Start date of the reverse stock split operation: February 27, 2019
Reverse stock split will bec ...
Professor Gareth Thomas of Southampton University Awarded Second Grant from Cancer Research UK for Further Evaluation of GKT831 in Oncology
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharma ...
International Nonproprietary Name "temelimab" Assigned to GNbAC1
Temelimab’s robust safety and tolerability profile confirmed
High-dose regimen fully validated by pharmacokinetic data
Enables higher dos ...
NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors
Dose-escalation part of study met primary objective
Study shows NP137 to hav ...